|
Age at diagnosis: median (range)
|
73
|
(57-83.0)
|
75
|
(59-82.0)
|
|
Diagnosis confirmed by: n (%)
| | | | |
|
Histology
|
164
|
(78.8)
|
112
|
(88.9)
|
|
Cytology
|
33
|
(15.9)
|
11
|
(8.7)
|
|
Clinical examination only
|
3
|
(1.4)
|
1
|
(0.8)
|
|
Information missing
|
8
|
(3.8)
|
2
|
(1.6)
|
|
Diagnosis suspected from: n(%)
| | | | |
|
PSA Screening
|
2
|
(1.0)
|
2
|
(1.6)
|
|
LUTS**
|
127
|
(61.1)
|
85
|
(67.5)
|
|
Other urological or skeletal symptoms
|
33
|
(15.9)
|
18
|
(14.3)
|
|
Incidentally discovered†
|
15
|
(7.2)
|
10
|
(7.9)
|
|
Other
|
7
|
(3.4)
|
6
|
(4.8)
|
|
Information missing
|
24
|
(11.5)
|
5
|
(4.0)
|
|
PSA-level***, ng/mL n (%)
| | | | |
|
≤4
|
8
|
(3.8)
|
6
|
(4.8)
|
|
4.1-10
|
24
|
(11.5)
|
18
|
(14.3)
|
|
10.1-20
|
31
|
(14.9)
|
25
|
(19.8)
|
|
20.1-100
|
41
|
(19.7)
|
33
|
(26.2)
|
|
> 100
|
23
|
(11.1)
|
14
|
(11.1)
|
|
Information missing
|
81
|
(38.9)
|
30
|
(23.8)
|
|
T-stage‡, n (%)
| | | | |
|
T0/T1ab
|
28
|
(13.5)
|
20
|
(15.9)
|
|
T1c
|
25
|
(12.0)
|
19
|
(15.1)
|
|
T2
|
89
|
(42.8)
|
55
|
(43.7)
|
|
T3-4
|
47
|
(22.6)
|
27
|
(21.4)
|
|
TX/Information Missing
|
19
|
(9.1)
|
5
|
(4.0)
|
|
N-stage‡, n (%)
| | | | |
|
N0
|
32
|
(15.4)
|
22
|
(17.5)
|
|
N1
|
12
|
(5.8)
|
5
|
(4.0)
|
|
NX
|
142
|
(68.3)
|
90
|
(71.4)
|
|
Information missing
|
22
|
(10.6)
|
9
|
(7.1)
|
|
M-stage‡in combination with PSA, n (%)
| | | | |
|
M0
|
88
|
(42.3)
|
61
|
(48.4)
|
|
MX, PSA ≤20
|
11
|
(5.3)
|
11
|
(8.7)
|
|
MX, 20 < PSA≤100
|
26
|
(12.5)
|
17
|
(13.5)
|
|
M1/PSA > 100
|
48
|
(23.1)
|
22
|
(17.5)
|
|
Information missing
|
35
|
(16.8)
|
15
|
(11.9)
|
|
Gleason score*, n(%)
| | | | |
|
2-6
|
50
|
(41.3)
|
41
|
(45.6)
|
|
7
|
20
|
(16.5)
|
17
|
(18.9)
|
|
8-10
|
31
|
(25.6)
|
26
|
(28.9)
|
|
Information missing
|
20
|
(16.5)
|
6
|
(6.7)
|
